Bristol-Myers Squibb Company
TREATMENT OF HODGKIN LYMPHOMA USING AN ANTI-PD-1 ANTIBODY

Abstract:

This disclosure provides to methods for treating Hodgkin lymphoma in a subject comprising nivolumab, a PD-1-blocking antibody, that inhibits tumor immune evasion in patients with relapsed or refractory Hodgkin's lymphoma.